XBIT - Enrollment underway in XBiotech's XB2001 study in pancreatic cancer

XBiotech (XBIT) has enrolled the first patient in its 1-BETTER study to evaluate XB2001 in combination with chemotherapy for treatment of Pancreatic Cancer. Safety and tolerability of the regimen, as well as progression-free survival, overall survival and time-to-treatment-failure will be assessed in the study.XBiotech’s anti-cancer agent, XB2001, is being assessed in combination with ONIVYDE + 5-FU/LV chemotherapy regimens. The study is also investigating a novel clinical endpoint that XBiotech calls the “clinical benefit response”, which involves radiological assessment of muscle mass and patient reported measures of pain, fatigue and appetite. The current study will commence with a Phase 1 portion to establish safety, tolerability and dosing of XB2001 in combination with ONIVYDE+5-FU/LV and will serve to establish a recommended Phase 2 dose, which will involve enrollment of 60 patients.

For further details see:

Enrollment underway in XBiotech's XB2001 study in pancreatic cancer